DS
Therapeutic Areas
Formycon AG Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FYB201 (Ranibizumab biosimilar) / YESAFILI® | Neovascular (wet) Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (mCNV) | Approved |
| FYB203 (Aflibercept biosimilar) | Neovascular (wet) AMD, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO) | Phase 3 |
| FYB202 (Bevacizumab biosimilar) | Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), Glioblastoma, Metastatic Renal Cell Carcinoma, Cervical Cancer | Phase 3 |
| FYB206 (Ustekinumab biosimilar) | Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis | Phase 3 |
| FB704A | Inflammatory and Autoimmune Diseases (e.g., Rheumatoid Arthritis) | Pre-clinical |
| FB101 | Non-alcoholic Steatohepatitis (NASH), Metabolic Diseases | Pre-clinical |
Leadership Team at Formycon AG
DC
Dr. Carsten Brockmeyer
Chief Executive Officer (CEO), Management Board
DN
Dr. Nicolas Combé
Chief Financial Officer (CFO), Management Board
DK
Dr. Karlheinz Schmelig
Chairman of the Supervisory Board
PD
Prof. Dr. Klaus Dugi
Deputy Chairman of the Supervisory Board
DF
Dr. Frank Mathias
Member of the Supervisory Board
DJ
Dr. Jochen Maas
Member of the Supervisory Board
DS
Dr. Stefan Glombitza
Former Chief Executive Officer (CEO)